Home
IMMX
IMMX News

Latest Immix Biopharma Inc. (IMMX) News on July 30, 2025

IMMX

Zacks

2 months ago

Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?

Immix Biopharma Attends FDA CEO Forum in Washington DC

IMMX

GlobeNewswire

2 months ago

Immix Biopharma Attends FDA CEO Forum in Washington DC

IMMX

Insider Monkey

2 months ago

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

IMMX

MT Newswires

2 months ago

Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis

$Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

IMMX

GlobeNewswire

2 months ago

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

IMMX

GlobeNewswire

2 months ago

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

$Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

IMMX

GlobeNewswire

2 months ago

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis$

IMMX

GlobeNewswire

2 months ago

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

IMMX

Simply Wall St.

2 months ago

We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

IMMX

GlobeNewswire

3 months ago

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

IMMX

MT Newswires

6 months ago

Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy

$Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis$

IMMX

GlobeNewswire

6 months ago

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Several Insiders Invested In Immix Biopharma Flagging Positive News

IMMX

Simply Wall St.

6 months ago

Several Insiders Invested In Immix Biopharma Flagging Positive News

IMMX

MT Newswires

7 months ago

Immix Biopharma Says Patients Dosed in AL Amyloidosis Trial Safety Run-in Successfully Complete Safety Evaluation

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

IMMX

GlobeNewswire

7 months ago

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

IMMX

MT Newswires

7 months ago

Immix Biopharma Reports Initial Data from US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis

$Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis$

IMMX

GlobeNewswire

7 months ago

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

$Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis$

IMMX

GlobeNewswire

7 months ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

IMMX

MT Newswires

8 months ago

Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower

$Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024$

IMMX

GlobeNewswire

8 months ago

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

IMMX

Simply Wall St.

8 months ago

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

IMMX

GlobeNewswire

8 months ago

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

$Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients$